Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
UNH kicks off Q3 earnings season today with its 8am ET call. More than 370 companies report across US and European markets this week. JNJ follows Tuesday, with banks dominating the rest of the week. BAC, STT, SCHW and BNY all report Wednesday and Thursday. Nordic lender Nordea Bank publishes Q3 results Thursday morning. Healthcare stocks are drawing the most constructive analyst attention heading into results. received an upgrade this week, with the consensus target lifting to $452.87.
Semiconductors are the week's most watched sector. NVDA and AMD sit at the top of negative options bets over the past seven days. South Korean tech shares fell more than 5% in a single session as AI-linked names sold off. WOLF (Wolfspeed) drew fresh short sellers, with short interest as a percentage of free float rising 3.7 points to 84.2%. That pattern runs counter to a broader short-covering trend: RDDT shorts trimmed positions from 16.1% to 15.2% of free float as the S&P 500 inclusion continues to squeeze bears out.
German battery-electric vehicle registrations hit 88,335 in September, up 95% year on year, according to Germany's vehicle registration authority. That is the largest September total since 2021. Finnish BEV registrations also hit a series high. The data points to a broad European EV upturn rather than a one-country effect.
On the deal front, ORTEX Index Rebalance Radar flags $1.9B of forced selling pressure building around Teck Resources if the Anglo American all-stock takeover closes by year-end. The deletion from the TSX 60 alone implies 11.7 days of normal trading volume to clear. The expected index announcement falls around 9 November. Travel stocks face a different headwind: BKNG and DAL both attracted analyst downgrades and put-side options interest this week, reflecting continued rotation away from consumer discretionary into healthcare and energy.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.